Literature DB >> 20156189

Lactococcus lactis as a cell factory for delivery of therapeutic proteins.

Mohammed Bahey-El-Din1, Cormac G M Gahan, Brendan T Griffin.   

Abstract

The food-grade bacterium Lactococcus lactis has been extensively investigated during the last two decades as a delivery vector for therapeutic proteins, DNA and vaccine antigens. The bacterium represents a safe, genetically tractable vector capable of producing heterologous therapeutic proteins at mucosal sites. Here we review recent work in which recombinant L. lactis strains have been exploited as agents to treat inflammatory bowel disease, allergy and cancer. We also describe the ability of L. lactis to deliver proteins with adjuvant potential, vaccines and DNA and discuss the therapeutic possibilities of this approach.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20156189     DOI: 10.2174/156652310790945557

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  25 in total

1.  Vaccines displaying mycobacterial proteins on biopolyester beads stimulate cellular immunity and induce protection against tuberculosis.

Authors:  Natalie A Parlane; Katrin Grage; Jun Mifune; Randall J Basaraba; D Neil Wedlock; Bernd H A Rehm; Bryce M Buddle
Journal:  Clin Vaccine Immunol       Date:  2011-11-09

Review 2.  Genome Editing of Food-Grade Lactobacilli To Develop Therapeutic Probiotics.

Authors:  Jan-Peter van Pijkeren; Rodolphe Barrangou
Journal:  Microbiol Spectr       Date:  2017-09

3.  Natural DNA Transformation Is Functional in Lactococcus lactis subsp. cremoris KW2.

Authors:  Blandine David; Amandine Radziejwoski; Frédéric Toussaint; Laetitia Fontaine; Marie Henry de Frahan; Cédric Patout; Sabine van Dillen; Patrick Boyaval; Philippe Horvath; Christophe Fremaux; Pascal Hols
Journal:  Appl Environ Microbiol       Date:  2017-08-01       Impact factor: 4.792

4.  Immunopathological evaluation of recombinant mycobacterial antigen Hsp65 expressed in Lactococcus lactis as a novel vaccine candidate.

Authors:  J C Herrera Ramírez; A Ch De la Mora; A De la Mora Valle; G Lopez-Valencia; R M B Hurtado; T B Rentería Evangelista; J L Rodríguez Castillo; A Rodríguez Gardea; S D Gómez Gómez; G E Medina-Basulto
Journal:  Iran J Vet Res       Date:  2017       Impact factor: 1.376

5.  Genome sequences of Lactococcus lactis MG1363 (revised) and NZ9000 and comparative physiological studies.

Authors:  Daniel M Linares; Jan Kok; Bert Poolman
Journal:  J Bacteriol       Date:  2010-07-16       Impact factor: 3.490

6.  PilVax: A Novel Platform for the Development of Mucosal Vaccines.

Authors:  Catherine Jia-Yun Tsai; Jacelyn M S Loh; Thomas Proft
Journal:  Methods Mol Biol       Date:  2022

7.  Protective effects of oral immunization with live Lactococcus lactis expressing Eimeria tenella 3-1E protein.

Authors:  Dexing Ma; Mingyang Gao; Rami A Dalloul; Junwei Ge; Chunli Ma; Jie Li
Journal:  Parasitol Res       Date:  2013-09-15       Impact factor: 2.289

8.  Lactic Acid Bacteria: a promising alternative for recombinant protein production.

Authors:  Elena García-Fruitós
Journal:  Microb Cell Fact       Date:  2012-12-12       Impact factor: 5.328

9.  Oral Administration of Lactococcus lactis Producing Interferon Type II, Enhances the Immune Response Against Bacterial Pathogens in Rainbow Trout.

Authors:  Alvaro Santibañez; Diego Paine; Mick Parra; Carlos Muñoz; Natalia Valdes; Claudia Zapata; Rodrigo Vargas; Alex Gonzalez; Mario Tello
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

10.  Immunomodulatory Activity of Lactococcus lactis A17 from Taiwan Fermented Cabbage in OVA-Sensitized BALB/c Mice.

Authors:  Hui-Ching Mei; Yen-Wenn Liu; Yi-Chin Chiang; Shiou-Huei Chao; Nai-Wen Mei; Yu-Wen Liu; Ying-Chieh Tsai
Journal:  Evid Based Complement Alternat Med       Date:  2013-01-21       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.